Acquisition of HRA Pharma

Established in 1996, headquartered in Paris with sales and marketing subsidiaries across Europe, HRA Pharma is a leading player in women’s health and rare diseases in endocrinology. The company is a European leader in emergency contraception, after developing the first levonorgestrel-based emergency contraceptive in 1999, now available in over 50 countries worldwide. HRA Pharma confirmed its pioneering role in the field of women’s health and endocrinology by introducing the new generation product ellaOne, an ulipristal acetate-based emergency contraceptive, and now available in over 80 countries. HRA has also developed and later out-licenced Esmya, a breakthrough innovation in non-surgical treatment of uterine fibroids. Over the last five years, HRA Pharma has set up a commercial infrastructure across eleven European countries through seven subsidiaries and has built a global distribution network for its products across 80 countries. The company has doubled its revenues over the past four years to reach 89M€ (+26% vs 2014) and expects to continue to expand at a rapid pace, driven by recent product launches, geographical expansion in particular in the US, and a rich and innovative development pipeline.